Oneness Biotech (TPEX:4743) - Hisse Senedi Fiyatı, Haberler ve Analizler

4743 Stoklara Genel Bakış

Oneness Biotech Co., Ltd. Tayvan'da yeni ilaçların, farmasötiklerin ve sağlık ürünlerinin araştırılması, geliştirilmesi ve satışı ile ilgilenmektedir.

Şirket hakkında

4743 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 86.94% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir geliri yok ( NT$102M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Oneness Biotech Co., Ltd. Rakipler

Caliway Biopharmaceuticals

TWSE:6919

NT$71.2b

Lotus Pharmaceutical

TWSE:1795

NT$70.0b

Lumosa Therapeutics

TPEX:6535

NT$58.7b

YungShin Global Holding

TWSE:3705

NT$15.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Oneness Biotech
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	NT$126.50
52 Haftanın En Yüksek Seviyesi	NT$241.44
52 Haftanın En Düşük Seviyesi	NT$125.00
Beta	1.49
11 Aylık Değişim	-10.92%
3 Aylık Değişim	-8.99%
1 Yıllık Değişim	-38.93%
33 Yıllık Değişim	-40.50%
5 Yıllık Değişim	467.04%
Halka arzdan bu yana değişim	897.75%

Son Haberler & Güncellemeler

Recent updates

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Mar 01

Hissedar Getirileri

	4743	TW Pharmaceuticals	TW Pazar
7D	-2.3%	-0.8%	-1.0%
1Y	-38.9%	9.3%	36.0%

Getiri vs. Endüstri: 4743 geçen yıl % 9.3 oranında getiri sağlayan TW Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 4743 geçen yıl % 36 oranında getiri sağlayan TW Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 4743's price volatile compared to industry and market?
4743 volatility
4743 Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	4.7%
Market Average Movement	5.5%
10% most volatile stocks in TW Market	8.7%
10% least volatile stocks in TW Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: 4743 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 4743 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	n/a	Shuling Cheng	www.onenessbio.com

Oneness Biotech Co., Ltd. Tayvan'da yeni ilaçların, farmasötiklerin ve sağlık ürünlerinin araştırılması, geliştirilmesi ve satışı ile ilgilenmektedir. Yeni İlaç Araştırma ve Geliştirme ve Tarımsal Ürün Yetiştirme segmentleri aracılığıyla faaliyet göstermektedir. Şirket, kronik diyabetik ayak ülserlerinin tedavisi için Faz III klinik çalışmalarında olan ON101'i ve Faz I klinik çalışmalarında olan bir anti-kanser ilacı olan OB318'i geliştirmektedir.

Oneness Biotech Co., Ltd. Temel Bilgiler Özeti

Oneness Biotech'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
4743 temel i̇stati̇sti̇kler
Piyasa değeri	NT$60.36b
Kazançlar(TTM)	-NT$978.89m
Gelir(TTM)	NT$101.93m

592.2x

P/S Oranı

-61.7x

F/K Oranı

4743 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
4743 gelir tablosu (TTM)
Gelir	NT$101.93m
Gelir Maliyeti	NT$52.77m
Brüt Kâr	NT$49.15m
Diğer Giderler	NT$1.03b
Kazançlar	-NT$978.89m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 11, 2024

Hisse başına kazanç (EPS)	-2.05
Brüt Marj	48.22%
Net Kâr Marjı	-960.39%
Borç/Özkaynak Oranı	0%

4743 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

4743 Stoklara Genel Bakış

Ödüller

Risk Analizi

Oneness Biotech Co., Ltd. Rakipler

TWSE:6919

NT$71.2b

TWSE:1795

NT$70.0b

TPEX:6535

NT$58.7b

TWSE:3705

NT$15.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

Recent updates

Price target decreased by 19% to NT$234

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Oneness Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 12, 2024

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oneness Biotech Co., Ltd. Agrees to Withdraw the 510(K) for Bonvadis Chronic Wound and Resubmit After the Supplementing Animal Study Data

US FDA Agrees Oneness Biotech Co., Ltd.'s S.C. Injection Formulation of FB825 to Proceed with Phase 2 Clinical Trial to Treat Moderate-To-Severe Atopic Dermatitis

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Oneness Biotech Co., Ltd. has filed a Follow-on Equity Offering.

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol Forsubcutaneous Injection Formulation of FB825 in Patientswith Moderate-To-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Oneness Biotech Co., Ltd. Obtains Import License in Thailand from Thai Food and Drug Administration

Price target decreased by 14% to NT$262

Consensus revenue estimates increase by 158%

Oneness Biotech Co., Ltd. Announces Approval of FESPIXON

New minor risk - Share price stability

New minor risk - Shareholder dilution

Oneness Biotech Co., Ltd. Submits 510(k) Application to the U.S. FDA to Expand the Intended Patient Population and Add Multiple Chronic Wound Indications for Bonvadis

New minor risk - Revenue size

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Price target decreased by 10% to NT$274

Oneness Biotech Co., Ltd. Announces Submission of Registration Application for Bonvadis, the Wound Care Topical Cream to the Drug Regulatory Authority of Pakistan (DRAP)

US FDA agrees to proceed with Phase 2 clinical trial for SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Oneness & Microbio (Shanghai)

Oneness Biotech Co., Ltd. Receives Approval from Malaysia NPRA for FESPIXON, the New Drug in Treatment of Diabetic Footulcers

Upcoming dividend of NT$0.098 per share

Oneness Biotech Co., Ltd. Announces Cash Dividend, Payable on July 21, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Oneness Biotech Co., Ltd., Annual General Meeting, Apr 18, 2023

Third quarter 2022 earnings released

Third quarter 2022 earnings released: EPS: NT$0.71 (vs NT$0.46 loss in 3Q 2021)

Microbio (Shanghai) and Oneness Co-Develop Broad-Spectrum siRNA (SNS812) to Treat SARS-CoV-2 Infection, Greenlighted by FDA to Proceed with A Phase I Study

Oneness Biotech Co., Ltd. Submits an IND to US FDA for A Phase Iclinical Trial on the Broad-Spectrum Anti-SARS-CoV-2siRNA (SNS812) Co-Developed with Microbio (Shanghai)

Second quarter 2022 earnings released: EPS: NT$0.87 (vs NT$1.24 loss in 2Q 2021)

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

Oneness Biotech Co., Ltd. Announces the By-Election of Lin, Yi-Fu as Director

First quarter 2022 earnings released: EPS: NT$1.01 (vs NT$0.31 in 1Q 2021)

Oneness Biotech Co., Ltd. Announces Food and Drug Administration Philippines Accepts NDA Application of Diabetic Foot Ulcer New Drug, Fespixon

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Oneness Biotech Co., Ltd. Announces The Malaysia National Pharmaceutical Regulatory Agency Accepts NDA Application of the Diabetic Foot Ulcer New Drug, Fespixon

Oneness Biotech Co., Ltd., Annual General Meeting, May 24, 2022

Oneness Biotech Co., Ltd. Announces the Data of Sns812 Were Published by EMBO Molecular Medicine

Oneness Biotech Co., Ltd. Announces the Partial Efficacy Data for the Phase 2a Study of FB825 in the Treatment of Atopic Dermatitis in the U.S

Third quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.064 profit in 3Q 2020)

Independent Director Kun-Ta Li has left the company

Second quarter 2021 earnings released: NT$1.24 loss per share (vs NT$1.40 profit in 2Q 2020)

Oneness Biotech Co., Ltd. Announces Phase 3 International MRCT Study Results of the Diabetic Foot Ulcer New Drug

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.54 loss in 1Q 2020)

Oneness Notified That FB704A Is Safe to Proceed with the Phase 2 Clinical Trial in Severe Asthma Under US FDA IND

Announcing: Oneness Biotech (GTSM:4743) Stock Soared An Exciting 936% In The Last Three Years

Full year 2020 earnings released: NT$0.68 loss per share (vs NT$1.28 loss in FY 2019)

Oneness Biotech Co., Ltd. Receives the Letter from MOHW Informing that ON101 for DFUs has Obtained the New Drug Approval Andits Drug Certificate Will Be Notified for Receipt

Oneness Biotech Co., Ltd., Annual General Meeting, May 21, 2021

Oneness Submits an IND to US FDA on Phase II Clinical Trial on Severe Asthma of FB704A

Oneness Will Not Proceed with the ON101 Phase3 Clinical Trial (ON101CLCT04) Application with BfArM of Germany Based on Strategic Consideration